NephJC is a not-for-profit organization and recognized by the US IRS as a 503c. All money raised is spent on the #NephTwitter community. NephJC is governed by a 5 member board of directors. Joel Topf, presidentSwapnil Hiremath, vice presidentMatt Sparks, treasurerAnna BurgnerMichelle Rheault, secretaryFunds are used to support the The Kidney Week and KIDNEYcon Tweet-ups. Money is used to help…
This week, we will discuss another IgA Nephropathy trial – Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.
PubMed® comprises more than 36 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text…
Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because…
To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients…
This week, we will discuss NEFIGARD, the trial of a targeted release steroid. It reduces proteinuria in IgA nephropathy – should it upstage humble prednisone?
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a…
This week, we will discuss NEFIGARD, the trial of a targeted release steroid. It reduces proteinuria in IgA nephropathy – should it upstage humble prednisone?
Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because…
To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients…
